Home › Funds › Eversept Partners, LP › BMRN
Eversept Partners, LP position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
Eversept Partners, LP reported holding 304,843 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$18.3M, representing 0.98% of its reported portfolio and ranking #29 among its reported holdings. Eversept Partners, LP has disclosed BMRN holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's BMRN position evolved
Eversept Partners, LP first disclosed a stake in BMRN in Q3 2025 at 146,642 shares (US$7.9M). The position peaked in Q3 2026 at 304,843 shares, worth US$18.3M. Across 5 filings, Eversept Partners, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 304,843 shares valued at US$18.3M — an increase of 55,236 shares quarter over quarter.. Notable position changes include a 36% trim in Q4 2025 (shares fell 5% over the following quarter), a 122% increase in Q1 2026 (shares rose 1% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 146.64K | $7.94M | New |
| Q4 2025 | 93.75K | $5.57M | Reduce |
| Q1 2026 | 207.77K | $11.74M | Add |
| Q2 2026 | 249.61K | $14.28M | Add |
| Q3 2026 | 304.84K | $18.29M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.99M sh · $899.34M · Q3 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Deep Track Capital, LP 6.37M sh · $382.46M · Q3 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held BMRN?
Eversept Partners, LP has disclosed BMRN holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Eversept Partners, LP's current position in BMRN?
As of Q3 2026, Eversept Partners, LP holds 304.84K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $18.29M, representing 0.98% of its reported portfolio and ranking #29.
Has Eversept Partners, LP been buying or selling BMRN?
In the latest 13F filing (Q3 2026), Eversept Partners, LP increased its position in BMRN. The position peaked in Q3 2026 at 304.84K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.